Polycythemia Vera

Polycythemia Vera (PV) is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells, and often white blood cells and platelets, by the bone marrow. This leads to an increased blood volume and viscosity, increasing the risk of thrombotic events and bleeding.

The exact cause of PV is largely unknown. The majority of cases (over 95%) are acquired and associated with a somatic mutation in the Janus kinase 2 (JAK2) gene, specifically the JAK2 V617F mutation. Rare cases may be due to other JAK2 mutations or mutations in other genes like CALR or MPL. It is not considered a hereditary disease.

In PV, hematopoietic stem cells acquire a mutation (most commonly JAK2 V617F) that leads to their uncontrolled proliferation. This results in an increased production of erythrocytes, granulocytes, and platelets. The elevated red blood cell mass increases blood viscosity, impairing blood flow, particularly in microcirculation. This can lead to ischemic events and thrombosis. Platelet dysfunction can also occur, paradoxically increasing the risk of both thrombosis and bleeding. Splenomegaly is common due to extramedullary hematopoiesis.

PV is a rare disease, with an incidence of approximately 0.5 to 1.5 per 100,000 person-years. It typically affects middle-aged and older adults, with a median age of diagnosis around 60 years. There is a slight male predominance.

• JAK2 V617F mutation (acquired somatic mutation)
• Advanced age

A. Early Symptoms

• Headache


• Dizziness


• Shortness of breath


• Visual disturbances (e.g., blurred vision) B. Common Symptoms


• Pruritus (itching), especially post-bathing (aquagenic pruritus)


• Splenomegaly (enlarged spleen)


• Fatigue


• Unexplained weight loss


• Abdominal pain or fullness C. Advanced Symptoms


• Erythromelalgia (burning pain in hands and feet, often with redness and swelling)


• Thrombotic events (e.g., stroke, heart attack, deep vein thrombosis, pulmonary embolism)


• Hemorrhagic events (e.g., nosebleeds, gastrointestinal bleeding) D. Emergency Symptoms


• Sudden onset of severe headache or neurological deficits (stroke symptoms)


• Chest pain (heart attack symptoms)


• Sudden severe shortness of breath or chest pain (pulmonary embolism)


• Profuse bleeding

• Vital Signs: May be normal or show hypertension.
• Inspection: Plethora (ruddy complexion), conjunctival injection, enlarged spleen (splenomegaly).
• Palpation: Palpable spleen, sometimes palpable liver.
• Auscultation: May reveal splenic bruits in cases of significant splenomegaly.

A. Clinical Assessment: History and physical examination, focusing on symptoms and risk factors.
B. Laboratory Testing: Complete blood count (CBC) with differential, JAK2 mutation analysis.
C. Imaging Studies: Ultrasound of the abdomen to assess spleen size.
D. Functional Tests: Not typically required for primary diagnosis.
E. Biopsy Findings: Bone marrow biopsy may show hypercellularity with increased erythroid, granulocytic, and megakaryocytic precursors, but is often not required if JAK2 mutation is present.
F. Genetic Testing: JAK2 V617F mutation analysis.
G. Differential Diagnosis: Essential to rule out other causes of erythrocytosis.

Test Name: Complete Blood Count (CBC) with Differential
Type: Blood Test
Purpose: To assess red blood cell count, hemoglobin, hematocrit, white blood cell count, and platelet count.
Expected Findings: Elevated hemoglobin and hematocrit levels (hemoglobin > 16.5 g/dL in men, > 16.0 g/dL in women; hematocrit > 49% in men, > 48% in women), leukocytosis, and thrombocytosis.
Interpretation: These findings are indicative of polycythemia. Test Name: JAK2 V617F Mutation Analysis
Type: Blood Test (genomic DNA extracted from leukocytes)
Purpose: To detect the presence of the JAK2 V617F mutation.
Expected Findings: Presence of the JAK2 V617F mutation.
Interpretation: Detection of this mutation in a patient with unexplained erythrocytosis strongly supports the diagnosis of PV.

Imaging Study: Abdominal Ultrasound
Purpose: To assess spleen size and detect splenomegaly, which is common in PV.
Typical Findings: Enlarged spleen (splenomegaly).
Clinical Importance: Helps confirm or assess the extent of organ involvement, but is not diagnostic on its own.

Polycythemia Vera is distinguished from secondary causes of erythrocytosis by the presence of JAK2 mutation, leukocytosis, thrombocytosis, and often splenomegaly. Secondary erythrocytosis can be caused by hypoxia (lung disease, high altitude, sleep apnea), kidney tumors, or the use of erythropoietin-stimulating agents. Other myeloproliferative neoplasms can have overlapping features.

• Thrombosis (e.g., stroke, myocardial infarction, DVT, PE)
• Hemorrhage (e.g., gastrointestinal bleeding, epistaxis)
• Splenomegaly leading to abdominal pain, early satiety, and portal hypertension
• Myelofibrosis (scarring of the bone marrow)
• Transformation to acute myeloid leukemia (AML)
• Gout and kidney stones due to increased cell turnover

A. Lifestyle Modifications: Avoiding dehydration, minimizing exposure to extreme heat or cold to reduce pruritus.
B. Preventive Measures: Management of cardiovascular risk factors.
C. Medical Treatment:
| Drug Class | Mechanism | Examples |
| :--------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :-------------- |
| Phlebotomy | Therapeutic removal of blood to reduce red blood cell mass and blood viscosity. | N/A |
| Hydroxyurea | Cytoreductive agent that inhibits DNA synthesis, reducing the production of blood cells by the bone marrow. | Hydroxyurea |
| Interferon-alfa | Modulates the immune system and has direct antiproliferative effects on hematopoietic stem cells. | Interferon-alfa |
| JAK Inhibitors | Target the abnormal signaling pathway driven by the JAK2 mutation, reducing the proliferation of malignant cells. | Ruxolitinib |
| Aspirin | Antiplatelet agent used to reduce the risk of thrombotic events. | Aspirin | D. Surgical Treatment: None specific for PV itself.
E. Interventional Procedures: None specific for PV itself.
F. Rehabilitation: Management of fatigue and other symptoms.
G. Emergency Management: Treatment of acute thrombotic or hemorrhagic events.

With modern treatment, the prognosis for patients with PV has significantly improved. Median survival is often over 10-15 years, and many patients live a near-normal lifespan. The main risks are complications of thrombosis, bleeding, and transformation to myelofibrosis or acute myeloid leukemia, which are less common.

Primary prevention is not possible as PV is caused by an acquired genetic mutation. Secondary prevention focuses on preventing thrombotic and hemorrhagic complications through regular monitoring and appropriate medical treatment (e.g., phlebotomy, low-dose aspirin, cytoreductive therapy).

The following homeopathic remedies have been historically indicated for symptoms associated with Polycythemia Vera. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Polycythemia Vera.